Lipocine (NASDAQ: LPCN) adds dealmaker Michael J. Grissinger to its board
Rhea-AI Filing Summary
Lipocine Inc. expanded its Board of Directors to five members and appointed Michael J. Grissinger as a director, effective August 3, 2026. The board determined that he qualifies as an independent director under Nasdaq listing standards.
Upon joining, Grissinger receives an initial stock option grant to purchase 2,000 shares of Lipocine common stock and an annual non-employee director cash retainer of $55,000. He brings extensive business development and M&A experience from senior roles at Johnson & Johnson and prior work at Ciba-Geigy, and currently serves on several public biotech boards.
Lipocine describes a pipeline of orally delivered drug candidates, including programs in postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis, and preterm birth, alongside its FDA-approved oral testosterone product TLANDO. The company furnished a press release detailing the appointment and its strategic rationale.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
independent director regulatory
Regulation FD regulatory
forward-looking statements regulatory
New Drug Application regulatory
hypogonadism medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What change did Lipocine (LPCN) make to its Board of Directors?
Lipocine expanded its Board to five members and appointed Michael J. Grissinger as a director effective August 3, 2026. He will serve until the next annual stockholder meeting or earlier termination events.
What compensation will Michael J. Grissinger receive from Lipocine (LPCN)?
Michael J. Grissinger will receive an initial stock option grant for 2,000 shares of Lipocine common stock and an annual non-employee director cash retainer of $55,000, in line with the company’s director compensation program.
Is Michael J. Grissinger considered independent on Lipocine’s (LPCN) board?
Yes. Lipocine’s Board of Directors determined that Michael J. Grissinger is an independent director under the listing standards of the Nasdaq Stock Market, meaning he meets the exchange’s criteria for director independence.
What relevant experience does Michael J. Grissinger bring to Lipocine (LPCN)?
Michael J. Grissinger spent over two decades at Johnson & Johnson in senior roles leading pharmaceutical licensing, corporate development, and M&A, and currently serves on multiple public biotech company boards, providing extensive dealmaking and governance experience.
What therapeutic areas are in Lipocine’s (LPCN) development pipeline?
Lipocine’s pipeline includes oral candidates for postpartum depression (LPCN 1154), major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis, and preterm birth, all leveraging its proprietary oral delivery technology platform.
Which approved product does Lipocine (LPCN) currently market?
Lipocine developed TLANDO, an oral prodrug of testosterone containing testosterone undecanoate, which is FDA-approved for adult males with conditions associated with endogenous testosterone deficiency, also known as hypogonadism.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
Commission
File No.
(State or other jurisdiction of incorporation) |
(IRS Employer Identification Number) |
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
Former name or former address, if changed since last report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices |
Appointment of Michael Grissinger as a Director
On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately. Mr. Grissinger will serve until the election of directors at the next annual meeting of the Company’s stockholders or until his earlier death, disqualification, resignation or removal. The Board of Directors has determined that Mr. Grissinger is an independent director under the listing standards of the Nasdaq Stock Market.
In connection with his appointment as a member of the Board of Directors, Mr. Grissinger will receive an initial stock option grant to purchase 2,000 shares of common stock of the Company. In addition, as a non-employee director he will receive an annual retainer of $55,000 per year.
There are no family relationships between Mr. Grissinger, and any director or executive officer of the Company and Mr. Grissinger does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.
On August 3, 2026, the Company issued a press release regarding the appointment of Mr. Grissinger to the Board of Directors. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report and Exhibit 99.1 hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information or that Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are filed with this report.
| Exhibit No. | Description | |
| 99.1 | Press Release announcing “Lipocine Announces Board of Director Appointment” | |
| 104 | Cover Page Interactive Date File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 3, 2026 | LIPOCINE INC. | |
| By: | /s/ Mahesh V. Patel | |
| Name: | Mahesh V. Patel | |
| Title: | President and Chief Executive Officer | |
Exhibit 99.1
Lipocine Inc.
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, August 3, 2026 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.
“We are pleased to welcome Mike Grissinger to our Board of Directors,” said Dana Ono, Ph.D., Chairman of the Board of Lipocine. “Mike brings extensive experience leading pharmaceutical licensing, corporate development, and mergers and acquisitions. As Lipocine works to advance the pipeline and pursue partnerships for our assets, his dealmaking experience and judgment will be invaluable.”
Mr. Grissinger spent more than two decades at Johnson & Johnson where he served in a variety of senior level management roles, including Vice President and Head of Worldwide Pharmaceutical Licensing and Vice President and Head of Worldwide Pharmaceutical Corporate Development and M&A. At Johnson & Johnson, Mr. Grissinger led the Immunology Therapeutic Area Business Development and Licensing Group and was also a member of the Immunology R&D/Commercial leadership team for Johnson & Johnson’s Worldwide Immunology Franchise. Prior to Johnson & Johnson, Mr. Grissinger spent 12 years at Ciba-Geigy in finance, marketing, and business development roles.
Mr. Grissinger is an experienced biotech company director serving on boards of public and private companies, including Board Chair roles. He currently serves on the board of directors at Aprea Therapeutics (Nasdaq: APRE) and Adicet Bio (Nasdaq: ACET). He also advises several privately-held biotech companies. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University – Fox School of Business.
Mr. Grissinger commented, “I am pleased to join the Board of Lipocine. The company has leveraged its innovative oral delivery technology to build a compelling portfolio of commercial and late-stage clinical assets with the potential to address significant unmet needs. I look forward to working with the Board and management team as they advance these programs to deliver meaningful value for patients and shareholders.”
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine’s development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder, LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107 our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our development of our products and product candidates and related efforts with the FDA, including the timing of clinical trials and regulatory submissions, the potential uses and benefits of our products and product candidates, the commercial potential for our product candidates, and potential strategic partnerships and other opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
SOURCE Lipocine Inc.
For further information:
Krista Fogarty
Phone: (801) 994-7383
kf@lipocine.com
Investors:
PJ Kelleher
Phone: (617) 430-7579
pkelleher@lifesciadvisors.com